- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Background Information
- Media Contact
Berlin, October 31, 2016 – Bayer is a founding member and Life Sciences partner of CUBE, a global start-up initiative headquartered in Berlin. Together with other representatives of industry and politics, the initiative opened the CUBE Cooperation Space in the center of Berlin, which is now available to start-ups, industrial companies and partners from the CUBE network as a venue for collaboration. In the future, selected start-ups will work together with companies in the cooperation space on cross-industry digitalization projects in the areas of life sciences, digital health and Industry 4.0. With the launch of collaborative projects between start-ups and industrial companies, CUBE is pursuing the goals of expanding and promoting innovation partnerships between industry leaders and innovative B2B start-ups.
Daniel Hartert, Chief Information Officer at Bayer AG and co-initiator of CUBE, sees additional potential for successfully advancing cross-industry networking with start-ups: “CUBE offers Bayer a wide variety of options for collaborating with industry-relevant, international start-ups. We combine our expertise with the inventiveness of talented people outside of Bayer to identify innovations as well as digital solutions in the fields of health and agriculture.” As a Life Sciences partner, Bayer plays an active role within the global network and will further expand the open innovation activities worldwide via its partnership with CUBE.
For Dr. Torsten Oelke, Executive Chairman of CUBE, the opening of the cooperation space is an important milestone for the initiative: “The do-it-yourself mindset is finally a thing of the past. Through CUBE, companies can make use of groundbreaking innovations from the best B2B start-ups in the world. The cooperation space in Berlin offers the ideal platform for this.”
Start-ups in the areas of life sciences, digital health, machinery and manufacturing as well as infrastructure and connectivity can apply for membership in the CUBE network. Moreover, CUBE has launched a competition with a prize of one million euros - one of the most generously endowed start-up awards worldwide. The award will be presented during the CUBE Berlin Tech Fair in May 2017. The prize money is intended to give the winner a high degree of independence and enable it to develop and expand partnerships with companies without having to seek further investments and investors in advance.
For more information, please visit www.innovate.bayer.com/what-we-offer/cube
CUBE is a global innovation ecosystem headquartered in Berlin that pursues the goals of initiating, establishing and strengthening partnerships between major industry players and start-ups in the areas of life sciences and digital health, machinery and manufacturing as well as infrastructure and connectivity.
The CUBE ecosystem brings all of the participants together and facilitates collaboration on innovative products and ideas.
As the future flagship event, the CUBE Berlin Tech Fair will take place for the first time from 10-12 May 2017.
For more information, please visit www.cube-global.com
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Business Services is the global in-house competence center for integrated business solutions and supporting business processes at Bayer. For more information, please visit www.business-services.bayer.com
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.